Integrating Imaging
and Omic Data

Data types in this case study: RNA-Seq, Digital Pathology, H&E, IHC, Proteomics

Case Study Highlight

Our client faced challenges with siloed multi-modal data, requiring integration for effective discovery use. Leveraging our domain expertise, we employed our cloud-based technology designed for managing complex datasets, along with our proficiency in AI-driven multi-modal analysis. This approach enabled their team to fully utilize their data for drug and biomarker discovery, leading to the identification of novel, clinically significant patient subgroups.

The Company

Our client is a leading innovator in oncology therapeutics, renowned for their dynamic development pipeline dedicated to targeted cancer therapies. With a specialized focus on creating new treatments for various solid tumors, a major strategy now involves the fusion of imaging and multi-omics data. This approach would significantly enhance the understanding of cancer biology, refine treatment precision, and offer tailored therapies suited to individual patient profiles. Additionally, these innovative methods hold the potential to advance early cancer detection and implement preventive strategies, marking a significant contribution to the evolution of cancer care.

"Choosing Sonrai was a strategic decision driven by their proven expertise in AI and precision medicine. Working with them has brought a level of innovation and insight into our data."

The Challenge

Our client conducted an internal assessment that revealed the inefficiencies, high costs, and slow pace of building in-house data solutions. Challenges included complex data management, time-intensive data analysis, resource-heavy processes, scalability issues, and risks of human error. These challenges underscored the need for a sophisticated AI partnership to keep pace with rapid advancements in precision medicine.

Some of the challenges identified included:

  • Multi-Modal Data Silos: Integrating diverse data types, such as genomic (RNA-Seq), proteomic (mass spec), and immunohistochemistry (IHC) imaging data, into a cohesive and interpretable format is a formidable task. Ensuring these data streams are compatible and can be analyzed together to yield meaningful insights requires advanced computational tools and expertise not available to the client.
  • Identifying Effective Drug Targets: Within the intricate landscape of oncology, identifying drug targets was challenging without comprehensive insights into molecular and anatomical characteristics.
  • Resource Intensiveness: Integrating multi-modal data requires significant computational resources and expertise in bioinformatics and data science. Our client lacked the necessary infrastructure and technical know-how, making it difficult to leverage the available data fully.
  • Interpretation Challenges: Even when data from different modalities are brought together, interpreting this integrated dataset can be challenging. It requires a deep understanding of both the biological implications and the technical aspects of the data, necessitating a multidisciplinary approach.
  • Scalability: As research progresses, the data generated can grow exponentially. Ensuring that the data integration processes are scalable and can handle increasing volumes of data is a significant challenge.
  • Delayed Decision-Making: The absence of integrated data hindered timely decision-making, causing prolonged development timelines and increased resource expenditure.
  • Collaboration Challenges: Working effectively with a range of partners presented challenges in aligning goals and coordinating activities across teams.

The Difference Sonrai Makes

Every organization is unique, and generic solutions fall short in addressing their distinct challenges. Sonrai is purpose-built to tackle the complexities of precision medicine, offering tailor-made solutions that align with your specific needs.

Discover Predictive Biomarkers 52% Faster

Sonrai’s AI technology supports rapid biomarker identification, empowering our partner to predict optimal therapy responses through an innovative toolkit.

57% Acceleration in MoA Studies

See how Sonrai unified diverse data sources to rapidly understand complex molecular pathways, helping identify predictive biomarkers and drug mechanisms of action.

14% Reduction in Preclinical Phase

Discover how Sonrai helps pharmaceutical companies overcome challenges in Invivo Drug Efficacy with AI-powered analytics.

Do These Challenges Sound Familiar?

Contact our friendly team for expert guidance and transformative insights.
"The analytics power of Sonrai Discovery has been groundbreaking for our data science team. We’re able to sift through complex datasets and pinpoint biomarkers with a level of accuracy we hadn't achieved before."

Sonrai's Integrated Approach:

Sonrai stood out as the ideal partner with our specialization in AI-driven precision medicine and expertise in integrating multi-modal data. Sonrai Discovery’s advanced AI algorithms and machine learning capabilities are specifically tailored for oncology research. Sonrai’s approach, emphasizing customized solutions and a collaborative mindset, provided scalable, efficient, and accurate data management. This alignment with the client’s needs positioned Sonrai as a strategic partner to enhance the drug development process significantly.

In partnering with Sonrai, our client immediately wished to focus on the identification of new effective drug targets. 

  • Multi-Modal Integration: Using Sonrai Discovery, our client first addressed the challenge of complex data management by quickly integrating their diverse data types, a very specialized capability. This included consolidating IHC images from a previous trial, protein expression data, clinical data and Next-Generation Sequencing (NGS) data into a cohesive framework.
  • Advanced Analytics and Correlation: Sonrai Discovery transformed how the client interpreted and performed cross-correlation analysis between molecular profiles and imaging data, facilitating the identification of correlations and patterns that would not have been possible. Explore more in Sonrai’s AI biomarker discovery workflow.
  • Enhanced Biomarker Management: As part of Sonrai’s comprehensive strategy in assisting the client, the incorporation of a biomarker management library played a pivotal role. This tool was instrumental in examining the expression of target genes across a spectrum of disease indications, significantly enhancing the client’s strategic approach to drug development.
  • Dynamic Cohort Exploration: The platform enabled intricate analyses without coding expertise, allowing the team to explore vast data types and construct cohorts for in-depth study.
  • Scalable Cloud Infrastructure: Sonrai’s cloud-based infrastructure allowed for efficient analysis and collaboration across teams, facilitating data access and reducing reliance on in-house IT resources.

View all your biomarkers across all your projects in one centralized location, maximizing output and reducing wasted time sifting through separate data

"The integration of imaging and omics data has been transformative for our approach to cancer therapy. How I have described it internally is like we've been given a key to unlock a deeper level of understanding of the disease, enabling us to tailor treatments with a precision we couldn't have imagined before."

Results and Impact:

Sonrai’s partnership has set the stage for transformative developments in the client’s oncology research. The client now has a better understanding of their drug targets and most importantly they’re picking the right patients for their drug.

  • Identifying New Drug Targets: By leveraging Sonrai’s integrated data approach, the client successfully identified effective drug targets to explore in the lab that were previously unavailable because of siloed data. 
  • Panel of Biomarkers Identification: A panel of candidate biomarkers of response was identified which could bested as secondary endpoints in pre-clinical models and potentially in future clinical trials.
  • Reproducibility: The use of Sonrai’s tools improved the reproducibility of findings, a crucial aspect in advancing reliable cancer research.
  • Precision in Treatment and Patient Selection: The integration approach led to a deeper understanding of disease mechanisms, enabling the tailoring of treatments with unprecedented precision and improving patient selection for clinical trials.
  • New biology: The use of Sonrai’s tools led to a better understanding of new drug’s mechanism of action. The ability to call on pathway databases directly from the platform led to fast biological insights

See an example of multi-omic analysis performed on the Sonrai Discovery platform in the form of this Weaver Plot created by the Sonrai Data Science team.

Discover how companies worldwide grow with Sonrai. Explore all our case studies.

Accelerating MoA Studies

Find out how our support facilitated the identification of predictive biomarkers, enhanced mechanism of action understanding, and accelerated R&D goals.

Biomarker Discovery Management

Centralized biomarker repository accelerates cross-referencing across projects and aids target selection for diagnostic tests.

AI Patient Stratification

Discover AI patient stratification in drug development - interactive visualizations, multimodal data integration, and transparent ML insights.

Get in touch

Like What You See? Let's Talk

We Listen to your problems
We give you confidence to make your decision